Table 1.
Microsatellite alterations observed in 20 ATLL patients
| Patient code | Clinicopathological variable | Microsatellite | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subtype | Stage | Age | Gender | PS | High LDH | High Ca | >3 lesions | Initial treatment | Response | HSCT | Outcome | D2S123 | D5S107 | D10S197 | D11S904 | D13S175 | |
| ATL01 | L | IV | 60 | M | 1 | + | − | + | mEPOCH | CR | − | Dead | − | MSI | − | − | − |
| ATL02 | L | II | 68 | M | 0 | − | + | − | mEPOCH | CR | − | Alive | LOH | − | LOH’ | − | − |
| ATL03 | A | IV | 36 | F | 1 | + | − | + | mEPOCH + RT + IT | PR | + | Alive | − | − | − | − | − |
| ATL04 | L | III | 67 | M | 1 | + | − | − | mEPOCH + RT | PR | − | Dead | − | − | LOH | − | − |
| ATL05 | A | IV | 63 | M | 1 | + | − | + | mEPOCH | CRu | − | Alive | LOH | − | LOH’ | − | − |
| ATL06 | L | III | 59 | F | 0 | + | − | − | mEPOCH | PR | − | Alive | LOH | − | − | − | − |
| ATL07 | L | III | 74 | M | 4 | + | + | + | mEPOCH | PD | − | Dead | MSI | − | − | − | − |
| ATL08 | A | IV | 81 | F | 2 | + | − | + | PVP | PR | − | Dead | − | − | − | − | LOH’ |
| ATL09 | A | IV | 56 | M | 0 | + | + | + | mEPOCH | PD | − | Dead | MSI | − | − | − | − |
| ATL10 | A | IV | 48 | F | 1 | + | + | + | mEPOCH + IT | CR | + | Alive | LOH | − | LOH | − | − |
| ATL11 | A | IV | 65 | F | 2 | + | − | + | mEPOCH | PD | + | Alive | − | − | − | − | − |
| ATL12 | L | IV | 75 | M | 2 | + | − | + | mEPOCH | PR | − | Dead | − | − | − | − | LOH’ |
| ATL13 | L | II | 77 | M | 0 | + | − | − | CHOP | CR | − | Alive | − | − | − | − | − |
| ATL14 | L | IV | 58 | M | 2 | + | − | + | mEPOCH | PR | + | Dead | − | − | − | − | − |
| ATL15 | L | III | 62 | M | 2 | + | − | + | mEPOCH | PD | − | Dead | − | − | − | − | − |
| ATL16 | A | IV | 70 | M | 4 | + | + | + | mEPOCH | NE | − | Dead | − | MSI | − | − | MSI |
| ATL17 | L | II | 73 | M | 3 | + | − | − | mEPOCH | PR | − | Dead | − | − | − | − | − |
| ATL18 | L | III | 55 | M | 1 | + | + | − | mEPOCH | PR | + | Alive | − | − | − | − | − |
| ATL19 | A | IV | 57 | F | 4 | + | + | + | mEPOCH | PR | + | Dead | − | − | − | − | − |
| ATL20 | L | IV | 71 | M | 3 | + | + | + | mEPOCH | PR | − | Dead | LOH | − | − | LOH’ | − |
A acute type, CHOP cyclophosphamide, doxorubicin, vincristine and prednisolone, CR complete remission, CRu uncertified complete remission, F female, High Ca hypercalcaemia, High LDH elevation of serum lactate dehydrogenase, HSCT allogeneic haematopoietic stem cell transplantation, IT intrathecal injection, L lymphoma type, LOH loss of heterozygosity, LOH′ alterations theoretically indistinguishable between Type A MSI and LOH, M male, mEPOCH etoposide, prednisolone, vincristine, doxorubicin and carboplatin, MSI microsatellite instability, NE not evaluated, PD progressive disease, PR partial remission, PS Eastern Cooperative Oncology Group performance status, PVP sobuzoxane and etoposide, RT radiotherapy, Stage Ann Arbor stage